.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place

Experts explore the growing role of CAR T-cell therapy in the treatment of r/r MM, as well as dive into recent data updates, importance of early referral, and future directions of CAR-T in this rapidly evolving field.

EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

March 31st 2025

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

March 31st 2025

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

EP. 3: Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

April 7th 2025

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

EP. 4: Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

April 7th 2025

Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.